Kings Path Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Kings Path Partners’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.25M	Hold	3,960	–	–	0.33%	35
2026 Q1	$749K	Hold	3,960	–	–	0.26%	41
2025 Q4	$749K	Hold	3,960	–	–	0.26%	41
2025 Q3	$701K	Sell	3,960 -1,105	-22%	-$164K	0.26%	40
2025 Q2	$576K	Hold	5,065	–	–	0.23%	49
2025 Q1	$533K	Sell	5,065 -3,195	-39%	-$361K	0.26%	51
2024 Q4	$885K	Hold	8,260	–	–	0.38%	69
2024 Q3	$827K	Buy	8,260 +1,380	+20%	+$139K	0.35%	76
2024 Q2	$580K	Buy	+6,880	New	+$547K	0.27%	90

Other funds holding LGND

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return

MNBTD

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

TAM

Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return

Kings Path Partners's LGND Position: Q2 2026 in Review

Kings Path Partners held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 3,960 shares worth $1.25M. The position accounts for 0.33% of the portfolio, ranked #35.

Kings Path Partners first reported a position in LGND in Q2 2024 and has held it in 9 quarters since. 53 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Kings Path Partners held 3,960 shares of Ligand Pharmaceuticals worth $1.25M as of Q2 2026.
Kings Path Partners left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
Ligand Pharmaceuticals made up 0.33% of Kings Path Partners's portfolio in Q2 2026, its #35 holding.
Kings Path Partners first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
53 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Kings Path Partners's 13F filing for Q2 2026, filed 14 Jul 2026.